Literature DB >> 25479114

Is lymphocyte adenosine a diagnostic marker of clinical malignant hyperthermia? A pilot study.

Saiid Bina1, John Capacchione, Bayarsaikhan Munkhuu, Sheila Muldoon, Rolf Bünger.   

Abstract

OBJECTIVE: Malignant hyperthermia is a pharmacogenetic disorder typically triggered by potent inhalation anesthetics and/or the depolarizing muscle relaxant succinylcholine in malignant hyperthermia-susceptible individuals. Since lymphocytes express the same Ca channel mutation found in malignant hyperthermia-susceptible muscle, we investigated agonist-induced adenosine formation in lymphocytes as an index of sarcoplasmic reticulum Ca-release-induced adenosine 5'-triphosphate turnover as a potential minimally invasive functional malignant hyperthermia assay.
DESIGN: Application of lymphocytes for malignant hyperthermia diagnosis.
SETTING: Hospitals and university laboratory.
SUBJECTS: Malignant hyperthermia-susceptible patients (n = 13) and normal subjects (n = 11).
INTERVENTIONS: Adenosine formation due to malignant hyperthermia-triggering agent halothane or the ryanodine receptor Ca channels agonist 4-chloro-m-cresol was compared in blood lymphocytes from malignant hyperthermia-susceptible patients and normal subjects.
MEASUREMENTS AND MAIN RESULTS: Cai and adenosine were measured in fresh or immortalized blood lymphocytes incubated with 0-10 mM 4-chloro-m-cresol or 0-10.7 mM halothane. Cai levels were significantly higher in immortalized malignant hyperthermia-susceptible B cells treated with 0.75 mM 4-chloro-m-cresol relative to controls. Similarly, at 1 mM 4-chloro-m-cresol or 0.96 mM halothane, adenosine levels were significantly higher in malignant hyperthermia-susceptible lymphocytes or immortalized B cells relative to controls. Receiver-operating characteristic analyses showed areas under the 4-chloro-m-cresol receiver-operating characteristic curves near more than or equal to 0.96 (p ≈ 0.0001), suggesting that 4-chloro-m-cresol-induced adenosine could readily distinguish between malignant hyperthermia-susceptible and normal controls cells.
CONCLUSIONS: Both 4-chloro-m-cresol and halothane caused adenosine accumulation in blood lymphocytes. Adenosine accumulation was markedly increased in malignant hyperthermia-susceptible lymphocytes compared with controls reflecting higher than normal adenosine 5'-triphosphate degradation in the malignant hyperthermia-susceptible cells. Although 4-chloro-m-cresol receiver-operating characteristic curves revealed that adenosine accumulation could readily distinguish between normal and malignant hyperthermia-susceptible lymphocytes, independent confirmation is required with a substantially larger number of enrolled subjects to correctly appreciate the clinical utility of the novel lymphocyte-adenosine protocol for malignant hyperthermia testing.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25479114     DOI: 10.1097/CCM.0000000000000744

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  3 in total

1.  Round Table on Malignant Hyperthermia in Physically Active Populations: Meeting Proceedings.

Authors:  Yuri Hosokawa; Douglas J Casa; Henry Rosenberg; John F Capacchione; Emmanuel Sagui; Sheila Riazi; Luke N Belval; Patricia A Deuster; John F Jardine; Stavros A Kavouras; Elaine C Lee; Kevin C Miller; Sheila M Muldoon; Francis G O'Connor; Scott R Sailor; Nyamkhishig Sambuughin; Rebecca L Stearns; William M Adams; Robert A Huggins; Lesley W Vandermark
Journal:  J Athl Train       Date:  2017-03-07       Impact factor: 2.860

2.  Hypermetabolism in B-lymphocytes from malignant hyperthermia susceptible individuals.

Authors:  Kerstin Hoppe; Guido Hack; Frank Lehmann-Horn; Karin Jurkat-Rott; Scott Wearing; Alberto Zullo; Antonella Carsana; Werner Klingler
Journal:  Sci Rep       Date:  2016-09-20       Impact factor: 4.379

3.  Clinical treatment of malignant hyperthermia in three cases.

Authors:  Tao Pan; Wenli Ji; Mengqi Nie; Yang Li
Journal:  Exp Ther Med       Date:  2016-09-16       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.